Septic shock: Advances in diagnosis and treatment

JAMA - Journal of the American Medical Association

Volumn 314, Issue 7, 2015, Pages 708-717

  Seymour, Christopher W ^a   Rosengart, Matthew R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DEXTRAN; DOPAMINE; GELATIN; HETASTARCH; NORADRENALIN; VASOACTIVE AGENT; CRYSTALLOID; ISOTONIC SOLUTION;

ARTERIAL PRESSURE; CARDIOGENIC SHOCK; CLINICAL FEATURE; CLINICAL PROTOCOL; CONSENSUS DEVELOPMENT; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FLUID THERAPY; HEMODYNAMIC MONITORING; HUMAN; HYPERLACTATEMIA; HYPOVOLEMIA; MEDICAL HISTORY; MENTAL HEALTH; META ANALYSIS (TOPIC); OLIGURIA; OUTCOME ASSESSMENT; PATIENT SELECTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TISSUE INJURY; PHYSIOLOGIC MONITORING; PROCEDURES; SHOCK, SEPTIC;

FLUID THERAPY; HUMANS; ISOTONIC SOLUTIONS; MONITORING, PHYSIOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, CARDIOGENIC; SHOCK, SEPTIC;

EID: 84940743799     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.7885     Document Type: Review

References (76)

1. Walley KR, Wood LDH, Shock. In: Hall J, Wood LDH, eds. Principles of Critical Care. New York, NY: McGraw Hill Co; 1998:277-301.
2. Millham FH. A brief history of shock. Surgery. 2010;148(5):1026-1037.
3. Manji RA, Wood KE, Kumar A. The history and evolution of circulatory shock. Crit Care Clin. 2009; 25(1):1-29.
4. Weil MH, Shubin H. Proposed reclassification of shock states with special reference to distributive defects. Adv Exp Med Biol. 1971;23(0):13-23.
5. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversiblemyocardial depression in patients with septic shock. Ann Intern Med. 1984; 100(4):483-490.
6. Murray CJ, Atkinson C, Bhalla K, et al; US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591-608.
7. Labovitz AJ, Noble VE, Bierig M, et al. Focused cardiac ultrasound in the emergent setting: a consensus statement of the American Society of Echocardiography and American College of Emergency Physicians. J Am Soc Echocardiogr. 2010;23(12):1225-1230.
8. Rochwerg B, Alhazzani W, Sindi A, et al; Fluids in Sepsis and Septic Shock Group. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med. 2014;161(5):347-355.
9. Rochwerg B, Alhazzani W, Gibson A, et al; FISSH Group (Fluids in Sepsis and Septic Shock). Fluid type and the use of renal replacement therapy in sepsis: a systematic review and networkmeta-analysis [published online April 23, 2015]. Intensive Care Med. doi:10.1007/s00134-015-3794-1.
10. Levy MM, Fink MP, Marshall JC, et al. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4): 1250-1256.
11. Tisherman SA, Barie P, Bokhari F, et al. Clinical practice guideline: endpoints of resuscitation. J Trauma. 2004;57(4):898-912.
12. Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring: task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014; 40(12):1795-1815.
13. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010;36(2):222-231.
14. Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012;25(4):609-634.
15. Rajaram SS, Desai NK, Kalra A, et al. Pulmonary artery catheters for adult patients in intensive care. Cochrane Database Syst Rev. 2013;2:CD003408.
16. Clermont G, Kong L, Weissfeld LA, et al; NHLBI ARDS Clinical Trials Network. The effect of pulmonary artery catheter use on costs and long-term outcomes of acute lung injury. PLoS One. 2011;6(7):e22512.
17. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA; Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303(8):739-746.
18. Zhang Z, Ni H, Qian Z. Effectiveness of treatment based on PiCCO parameters in critically ill patients with septic shock and/or acute respiratory distress syndrome: a randomized controlled trial. Intensive Care Med. 2015;41(3):444-451.
19. Richard JC, Bayle F, Bourdin G, et al. Preload dependence indices to titrate volume expansion during septic shock: a randomized controlled trial. Crit Care. 2015;19(1):5.
20. Jansen TC, van Bommel J, Schoonderbeek FJ, et al; LACTATE study group. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010;182(6):752-761.
21. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
22. Wiener RS, Welch HG. Trends in the use of the pulmonary artery catheter in the United States, 1993-2004. JAMA. 2007;298(4):423-429.
23. Takala J, Ruokonen E, Tenhunen JJ, Parviainen I, Jakob SM. Early non-invasive cardiac output monitoring in hemodynamically unstable intensive care patients: a multi-center randomized controlled trial. Crit Care. 2011;15(3):R148.
24. Garcia X, Gruartmoner G. Clinical Trials.gov website. Monitoring resuscitation in severe sepsis and septic shock (NCT01747057). https://clinicaltrials.gov/ct2/show/NCT01747057?term=nct01747057&rank=1. Accessed July 15, 2015.
25. Pearse RM, Harrison DA, MacDonald N, et al; OPTIMISE Study Group. Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review. JAMA. 2014;311(21):2181-2190.
26. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726-1734.
27. Liu V, Morehouse JW, Soule J, Whippy A, Escobar GJ. Fluid volume, lactate values, and mortality in sepsis patients with intermediate lactate values. Ann Am Thorac Soc. 2013;10(5):466-473.
28. Puskarich MA, Trzeciak S, Shapiro NI, Heffner AC, Kline JA, Jones AE; Emergency Medicine Shock Research Network (EMSHOCKNET). Outcomes of patients undergoing early sepsis resuscitation for cryptic shock compared with overt shock. Resuscitation. 2011;82(10):1289-1293.
29. Gomez H, Kellum JA. Lactate in sepsis. JAMA. 2015;313(2):194-195.
30. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(21):2063.
31. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23): 2594-2605.
32. Wong HR, Cvijanovich NZ, Allen GL, et al. Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med. 2011;39(11):2511-2517.
33. Langley RJ, Tsalik EL, van Velkinburgh JC, et al. An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med. 2013;5 (195):195ra95.
34. Bulger EM, May S, Kerby JD, et al; ROC investigators. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg. 2011;253(3):431-441.
35. Yealy DM, Kellum JA, Huang DT, et al; ProCESS Investigators. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370 (18):1683-1693.
36. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311 (13):1308-1316.
37. Myburgh JA, Mythen MG. Resuscitation fluids. N Engl J Med. 2013;369(25):2462-2463.
38. Morgan TJ. The ideal crystalloid-what is 'balanced'? Curr Opin Crit Care. 2013;19(4):299-307.
39. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012;308(15):1566-1572.
40. Young P. Australian New Zealand Clinical Trials Registry website. 0.9%Saline vs Plasma-Lyte 148 for intensive care fluid therapy: the SPLIT study. ID: ACTRN12613001370796. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365460. Accessed June 4, 2015.
41. Reddy SK, Bailey MJ, Beasley RW, et al. A protocol for the 0.9%saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study. Crit Care Resusc. 2014;16(4):274-279.
42. Finfer S, Liu B, Taylor C, et al; SAFE TRIPS Investigators. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care. 2010;14(5):R185.
43. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med. 2011;3(88):88ps25.
44. Caironi P, Tognoni G, Masson S, et al; ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370(15):1412-1421.
45. Annane D, Siami S, Jaber S, et al; CRISTAL Investigators. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA. 2013;310(17): 1809-1817.
46. Myburgh JA, Finfer S, Bellomo R, et al; CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367(20):1901-1911.
47. Perner A, Haase N, Guttormsen AB, et al; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2): 124-134.
48. Perner A, Haase N, Winkel P, et al. Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate. Intensive Care Med. 2014;40(7):927-934.
49. De Backer D, Biston P, Devriendt J, et al; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.
50. Mouncey PR, Osborn TM, Power GS, et al; PROMISE Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372(14):1301-1311.
51. Peake SL, Delaney A, Bailey M, et al; ARISE Investigators; ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. N Engl JMed. 2014;371(16):1496-1506.
52. Asfar P, Meziani F, Hamel JF, et al; SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370(17):1583-1593.
53. Andrews B, Muchemwa L, Kelly P, Lakhi S, Heimburger DC, Bernard GR. Simplified severe sepsis protocol: a randomized controlled trial of modified early goal-directed therapy in Zambia. Crit Care Med. 2014;42(11):2315-2324.
54. Holst LB, Haase N, Wetterslev J, et al; TRISS Trial Group; Scandinavian Critical Care Trials Group. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371 (15):1381-1391.
55. Siegemund M. Clinicaltrials.gov website. Basel Study for Evaluation of Starch (130;0.4) Infusion in Septic Patients: BASES (130;0.4) Trial. https://clinicaltrials.gov/ct2/show/NCT00273728?term=NCT00273728&rank=1. Accessed July 16, 2015.
56. De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: ameta-analysis. Crit Care Med. 2012;40(3):725-730.
57. Polito A, Parisini E, Ricci Z, Picardo S, Annane D. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Med. 2012;38(1):9-19.
58. Serpa Neto A, Nassar AP, Cardoso SO, et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care. 2012;16 (4):R154.
59. Huang DT, Angus DC, Barnato A, et al; ProCESS/ARISE/ProMISe Methodology Writing Committee. Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of PROCESS, ARISE, and PROMISE. Intensive Care Med. 2013;39(10): 1760-1775.
60. Angus DC, Barnato AE, Bell D, et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, PROCESS and PROMISE Investigators [published online May 8, 2015]. Intensive Care Med. doi:10.1007/s00134-015-3822-1.
61. Zhang L, Zhu G, Han L, Fu P. Early goal-directed therapy in the management of severe sepsis or septic shock in adults: ameta-analysis of randomized controlled trials. BMC Med. 2015;13:71.
62. Rusconi AM, Bossi I, Lampard JG, Szava-Kovats M, Bellone A, Lang E. Early goal-directed therapy vs usual care in the treatment of severe sepsis and septic shock: a systematic review and meta-analysis [published online May 16, 2015]. Intern Emerg Med. doi:10.1007/s11739-015-1248-y.
63. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345 (19):1368-1377.
64. Lewis RJ. Disassembling goal-directed therapy for sepsis: a first step. JAMA. 2010;303(8):777-779.
65. D'Aragon F, Belley-Cote EP, Meade MO, et al; Canadian Critical Care Trials Group. Blood pressure targets for vasopressor therapy: a systematic review. Shock. 2015;43(6):530-539.
66. Opal SM, Laterre PF, Francois B, et al; ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013; 309(11):1154-1162.
67. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055-2064.
68. Patel GP, Balk RA. Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med. 2012;185(2):133-139.
69. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.
70. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009;301(22):2362-2375.
71. Wang C, Sun J, Zheng J, et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: ameta-analysis of randomized controlled trials. Anesth Analg. 2014;118(2):346-357.
72. Lipcsey M, Chiong J, Subiakto I, Kaufman MA, Schneider AG, Bellomo R. Primary fluid bolus therapy for infection-associated hypotension in the emergency department. Crit Care Resusc. 2015;17 (1):6-11.
73. Hernandez G, Bruhn A, Luengo C, et al. Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study. Intensive Care Med. 2013;39(8):1435-1443.
74. Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011;39(2):259-265.
75. Shankar-Hari M, Deutschman CS, Singer M. Do we need a new definition of sepsis? Intensive Care Med. 2015;41(5):909-911.
76. Hoste EA, Maitland K, Brudney CS, et al; ADQI XII Investigators Group. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth. 2014;113(5):740-747.